Prakash P Doke
Biographic Data
| ID | 10035973 |
|---|---|
| NAME | Prakash P Doke |
| GIVEN NAMES | Prakash P |
| FAMILY NAME | Doke |
| SIGNATURE | DOKE P P |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Sars-CoV-2 breakthrough infections during the second wave of Covid-19 at Pune, India
Breakthrough infections following SARS-CoV-2 vaccination remain the global concern. The current study was conducted during the second wave of COVID-19 (1st March−7th July 2021) in Pune, India, at two tertiary care hospitals. Of the 6,159 patients diagnosed as COVID-19, 372/2,210 (16.8%) were breakthrough infections. Of these, 81.1 and 18.8% received one or two doses of Covishield or Covaxin, respectively. Of note, 30.7% patients were with comorbi…
No prominent works on this page.
Sars-CoV-2 breakthrough infections during the second wave of Covid-19 at Pune, India
Breakthrough infections following SARS-CoV-2 vaccination remain the global concern. The current study was conducted during the second wave of COVID-19 (1st March−7th July 2021) in Pune, India, at two tertiary care hospitals. Of the 6,159 patients diagnosed as COVID-19, 372/2,210 (16.8%) were breakthrough infections. Of these, 81.1 and 18.8% received one or two doses of Covishield or Covaxin, respectively. Of note, 30.7% patients were with comorbi…
Antibody (1 work) · Comorbidity (1 work) · COVID-19 Clinical Research Studies (1 work) · Disease (1 work) · Immunization (1 work) · Immunology (1 work) · Internal Medicine (1 work) · Kappa (1 work) · Medicine (1 work) · SARS-CoV-2 and COVID-19 Research (1 work)